Sec Form 4 Filing - Sim Brandon @ Astrana Health, Inc. - 2024-11-08

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Sim Brandon 2. Issuer Name and Ticker or Trading Symbol Astrana Health, Inc. [ ASTH] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) CEO and President (Last) (First) (Middle) C/O ASTRANA HEALTH, INC., 1668 S. GARFIELD AVENUE, 2ND FLOOR 3. Date of Earliest Transaction (MM/DD/YY) 11/08/2024 (Street) ALHAMBRA, CA91801 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 11/08/2024 A 34,386 ( 3 ) A $ 0 983,372 ( 4 ) ( 5 ) D Common Stock 258,824 ( 1 ) I By Sim Family Irrevocable Trust 2021 Common Stock 392,816 ( 2 ) I By Brandon Sim 2020 Irrevocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Sim Brandon C/O ASTRANA HEALTH, INC. 1668 S. GARFIELD AVENUE, 2ND FLOOR ALHAMBRA, CA91801 CEO and President Signatures /s/ Kathy Diep, as Attorney-in-Fact 11/12/2024 Signature of Reporting Person Date

Explanation of Responses:

( 1 )These securities are held by the Sim Family Irrevocable Trust 2021. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. ( 2 )These securities are held by the Brandon Sim 2020 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. ( 3 )Represents a grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Provided the Reporting Person is still employed with the Issuer on the date of vesting, the shares shall vest in eight equal installments, with the first installment vesting on November 8, 2024, and the remaining shares vesting in seven equal semi-annual installments beginning on April 2, 2025. ( 4 )Includes 497,999 shares of unvested restricted stock, which will vest as follows (in each case subject to continuous employment with the Issuer): (i) 54,280 shares, which will vest in two equal annual installments on June 27, 2025 and 2026; (ii) 5,557 shares, which will vest in two equal annual installments on June 27, 2025 and 2026; (iii) 85,513 shares, which will vest in five equal semi-annual installments, beginning March 31, 2025; and (iv) grants of 99,255 shares, 10,160 shares and 243,234 shares, each of which will vest upon achievement of certain pre-established performance goals. Also includes 105,605 restricted stock units, which will vest in seven equal semi-annual installments beginning on April 2, 2025 (subject to continuous employment with the Issuer). ( 5 )Includes 644 shares acquired under the Issuer's Employee Stock Purchase Plan.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.